Abstract 1067
Background
To report on the local response (LR), biochemical progression-free (bPFS) and distant-progression free (DPFS) survival after stereotactic body radiotherapy (SBRT) for bone and lymph node prostate cancer oligometastases.
Methods
Within the context of a prospective SBRT trial for oligometastases (NCT03486431), 54 bone and lymph node oligometastases, all detected on PSMA-PET/CT, were irradiated in 40 prostate cancer patients between July 2017 and December 2018. Of these patients, 35 had hormone-sensitive and 5 had castration-resistant disease. Short-term concomitant ADT was recommended in all hormone-naïve patients but decided in consultation with the patient. Ultimately, 20 patients received ADT while 20 did not. The two groups were well balanced, with no significant differences in age, Gleason score, PSA, lesion type, number or timing of metastases, and fractionation schedule. All patients received a PSMA-PET/CT at 6 months after SBRT. PSMA-RADS v1.0 was used to categorize the response of the treated lesion. Quality-of-life (QOL) scoring was performed using the EORTC QLQ-C30 questionnaire at baseline, 3 and 6 months.
Results
Median follow-up for all patients was 9.6 months (IQR 6.3 – 12.9 months). Up till now, 42 lesions could be reevaluated at 6 months after SBRT with PSMA-PET/CT, of which 30 showed complete response, 8 partial response and 4 stable disease. No symptomatic or local progression was observed in the irradiated lesions. There was no statistically significant influence of ADT, fractionation, type of lesion or lesion size on LR. Patients who received ADT had significantly improved bPFS (median bPFS of 6.9 months versus median not reached; p = 0.0017) and DPFS (median DPFS of 6.8 months versus 17.3 months; p = 0.0021). We did not observe any clinically relevant changes in QOL scores between the patients who received ADT versus those who refused. Overall, QOL scores remained stable for both groups at baseline, 3 and 6 months.
Conclusions
These prospective data, although non-randomized, suggest that oligometastatic prostate cancer patients treated with SBRT could potentially benefit from short-term ADT. Longer follow-up will determine if ADT simply delays progression or truly alters the course of the disease.
Clinical trial identification
NCT03486431.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract